Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International Registry
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02907398|
Recruitment Status : Recruiting
First Posted : September 20, 2016
Last Update Posted : March 1, 2018
Inspire intends to conduct this registry to: 1) collect Inspire therapy clinical evidence in the clinical practice setting; 2) collect additional information on the effectiveness, use and safety in the commercial setting; and 3) engage physician customers to report the collective outcome within a group of properly trained programs that utilize Inspire therapy on a regular basis.
In addition, a sub-study will be conducted under this Registry at a limited number of Registry centers and will include a cohort of Registry patients and a cohort of patients who have not received the Inspire therapy device due to denial of insurance coverage. The two sub-study cohorts' quality of life and AHI data will be compared.
|Condition or disease||Intervention/treatment|
|Obstructive Sleep Apnea||Device: Inspire therapy Other: No intervention|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||2500 participants|
|Target Follow-Up Duration:||12 Months|
|Official Title:||Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International Registry|
|Actual Study Start Date :||October 19, 2016|
|Estimated Primary Completion Date :||September 2018|
|Estimated Study Completion Date :||September 2019|
This group will include 250 patients who have been implanted with the Inspire therapy system, enrolled in the ADHERE Registry, and are willing to complete a follow-up home sleep apnea test (HSAT).
Device: Inspire therapy
Other Name: ADHERE
This group will include 100 patients who have been denied insurance coverage of the Inspire therapy system implant by their provider, have had no intervention (Inspire), and are willing to complete a HSAT and provide information about their OSA treatment after denial.
Other: No intervention
Other Name: CONTROL
- Change in Apnea Hypopnea (AHI) from Baseline to 12-Months [ Time Frame: Baseline through 12 months ]Apnea Hypopnea Index (AHI) is a measure of OSA severity. The AHI will be determined by the AHI score at the post-titration visit compared with the pre-implant baseline score.
- Change in Epworth Sleepiness Scale (ESS) from Baseline to 12 Months [ Time Frame: Baseline through 12 months ]The Epworth Sleepiness Scale (ESS) is a validated instruction that rates a subject's daytime sleepiness. The ESS efficacy endpoint will be determined by the ESS score at the 12-month follow-up as compared to baseline.
- Patient Experience with Therapy (PET) [ Time Frame: Through 12 months ]The PET is a survey deigned to collect information about patients' experience with the Inspire therapy. Information will be collected once the therapy is activated about relative satisfaction with the therapy over time.
- Therapy Adherence [ Time Frame: Through 12 months ]Therapy use, reported as hours of use per week, is record by Inspire device and can be collected upon interrogation of the device in the clinic. This value can be used to quantify device use and adherence over time.
- Advance or Additional Titrations [ Time Frame: Through 12 months ]The patient will report the number of in-office or sleep lab device titrations completed.
- Physical Assessment [ Time Frame: Baseline through 12 months ]Blood pressure, and height (in either cm or in) & weight (in either kg or lbs) will be used to calculate Body Mass Index at baseline and through study completion.
- Clinical Global Impression (CGI-I) [ Time Frame: Baseline through 12 months ]The CGI-I is a seven point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.
- Device Data Collection [ Time Frame: Through 12 months ]Device programming and adjustment data recorded during follow-up visits will be collected from physician and patient programmers.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02907398
|Contact: Amy Geisfirstname.lastname@example.org|
|United States, Alabama|
|The University of Alabama for the University of Alabama at Birmingham||Recruiting|
|Birmingham, Alabama, United States, 35294-0111|
|Principal Investigator: Kirk Withrow, MD|
|United States, California|
|University of Southern California||Recruiting|
|Los Angeles, California, United States, 90032|
|Principal Investigator: Eric Kezirian, MD|
|United States, District of Columbia|
|MedStar Washington Hospital Center||Recruiting|
|Washington, District of Columbia, United States, 20010|
|Principal Investigator: Stanley H. Chia, MD|
|United States, Florida|
|University of Florida Health||Recruiting|
|Gainesville, Florida, United States, 32611|
|Contact: Margaret Hamer 352-294-5685 email@example.com|
|Principal Investigator: John Harwick, MD|
|United States, Kansas|
|Kansas University Medical Center||Recruiting|
|Kansas City, Kansas, United States, 66160|
|Contact: Bryan Humphrey 913-588-3759 firstname.lastname@example.org|
|Principal Investigator: Christopher Larsen, MD|
|United States, Minnesota|
|University of Minnesota||Recruiting|
|Minneapolis, Minnesota, United States, 55455|
|Contact: Cheryl Stibbe 612-625-1435 email@example.com|
|Principal Investigator: Conrad Iber, MD|
|United States, New York|
|Cornell University||Not yet recruiting|
|New York, New York, United States, 10065|
|United States, Ohio|
|University Hospitals Cleveland Medical Center||Recruiting|
|Cleveland, Ohio, United States, 44106|
|Contact: Mary Andrews 216-844-2386 Mary.Andrews@UHhospitals.org|
|Contact: Stacy Pot Stacy.Pot@UHhospitals.org|
|Principal Investigator: Kingman Strohl, MD|
|Sub-Investigator: Mark Weidenbecher, MD|
|United States, Pennsylvania|
|University of Pennsylvania||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104-6061|
|Contact: Nadia Azad Nadia.Azad@uphs.upenn.edu|
|Principal Investigator: Richard Schwab, MD|
|Thomas Jefferson University and Hospital||Recruiting|
|Philadelphia, Pennsylvania, United States, 19107|
|Contact: Beth Duddy 215-503-6828 firstname.lastname@example.org|
|Principal Investigator: Maurits Boon, MD|
|University of Pittsburgh||Recruiting|
|Pittsburgh, Pennsylvania, United States, 15213|
|Contact: Tina Harrison 412-232-7207 email@example.com|
|Principal Investigator: Ryan Soose, MD|
|University of Lubeck||Recruiting|
|Lubeck, Germany, 23562|
|Principal Investigator: Armin Steffen, PD Dr. med.|
|Mannheim, Germany, 68167|
|Contact: Oliver Schmidt Oliver.Schmidt@umm.de|
|Principal Investigator: Joachim Maurer, MD|
|Klinikum rechts der Isar der Technischen Universitat Munchen||Recruiting|
|Munich, Germany, 81675|
|Principal Investigator: Clemens Heiser, PD Dr. med.|
|Study Director:||Quan Ni, PhD||Inspire Medical Systems, Inc.|